



SEQUENCE LISTING

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

<110> Pfizer Products Inc.

<120> TACE INHIBITORS

<130> PC10240A

<140> 09/373,182

<141> 1999-08-12

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Prepared by
PCR Synthesis; Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2

<400> 1

Pro Leu Gly Leu Ala Arg

1

5

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Prepared by PCR
Synthesis; Dnp-Pro-Cha-Gly-Cys (Me) -His-Ala-Lys (NMA)
-NH2

<400> 2

Pro Gly Cys His Ala Lys

1

5

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Prepared by PCR
Synthesis; Ac-Pro-Leu-Gly-SCH[CH₂CH(CH₃)₂]CO-Leu-Gl
y-OC₂H₅

<400> 3

Pro Leu Gly Leu Gly

1

5

<210> 4

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Prepared by PCR
Synthesis;
LY-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Lys (CMTR) -Arg
(LY=Lucifer Yellow; CMTR= 5-carboxytetramethyl
Rhodamine))

<400> 4

Leu Ala Gln Ala Val Arg Ser Ser Lys Arg

1

5

10